The case for & against
Bull & Bear analysis
Biogen Inc. (NASDAQ: BIIB) is a leading biotechnology company focusing on innovative therapies for neurological diseases such as multiple sclerosis (MS), Alzheimer's disease, and spinal muscular atrophy (SMA). The company is recognized for its robust pipeline aimed at addressing unmet medical needs, particularly in neurology and rare diseases. Biogen's recent strategic pivot towards high-growth products, such as Lekembi and Zerzuve, reflects its commitment to innovation and position within the evolving biopharmaceutical landscape, particularly as it navigates the competitive pressures facing its traditional MS portfolio.
Bull says
- ↑Q1 2026 revenue $2.5B (+2% YoY) and GAAP diluted EPS $2.15 (+31% YoY)
- ↑Growth products (Lekembi, Zerzuve) delivered $851M revenue with 80% treatment persistence at 18 months
- ↑FDA approved subcutaneous Lekembi formulation for U.S. launch in Aug 2026, boosting convenience and uptake
- ↑Multiple late-stage pipeline readouts in 2026 position Biogen for additional approvals and revenue growth
- ↑Anti-amyloid market expanding ~15% QoQ, where Biogen holds a leading Alzheimer’s therapy share
- ↑Strong cash flow ($594M in Q1 2026) and solid balance sheet underpin continued R&D investment
Bear says
- ↓MS portfolio revenue declined 11% YoY due to generic competition, notably in Europe
- ↓Analysts project Q2 2026 adjusted EPS ~$3.24, a ~40.8% YoY decrease, indicating earnings risk
- ↓Profitability concerns arise from rising operating costs and margin pressure
- ↓Pipeline execution risks remain high as registrational studies for key programs start in 2026
- ↓Institutional ownership has weakened, potentially limiting stock momentum
- ↓Persistent generic and competitor pressures in neurology may constrain long-term market share
Investment themes with BIIB
Genetic and drug innovations driving medical breakthroughs
Earnings Call · Q1 2026 · Mgmt. Guidance
Transcript signals
Bull points
- This was a very strong quarter for Biogen from a development standpoint, with meaningful progress across both our marketed products and our late-stage pipeline.
- First, the U.S. approval of high-dose Spinraza represents a meaningful advancement for people living with SMA and reinforces Biogen's leadership in the category.
- Additionally, in Alzheimer's disease, new real-world data for Lekembe show strong treatment persistence with nearly 80% of patients remaining on therapy at 18 months and almost 70% at two years.
Bear points
- we recorded approximately 34 million dollars of acquired IPR&D in the first quarter of 2026 related primarily to our altogen and alloy transaction resulting in approximately 20 cents per share impacted GAAP and non-GAAP EPS.